New (Pazopanib Tablets 200 mg A217517 1)
Pazopanib Tablet, Film Coated
Product Images NDC 0480-4184
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Pazopanib (NDC 0480-4184). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
1 (Pazopanib Tablets 200 mg A217517 2)
22 (Pazopanib Tablets 200 mg A217517 3)
This text provides information on a proportion progression-free study comparing the effectiveness of Pazopanib (N = 246) versus Placebo (N = 123). The median progression-free survival for Pazopanib was 4.6 months, while for Placebo it was 1.6 months. The hazard ratio between the two groups was 0.35, with a 95% confidence interval of 0.26 to 0.48, indicating a significant difference between the two treatments.*
New (Pazopanib Tablets 200 mg A217517 4)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
